Evidence check: CYP2D6 in the context of Abnehmen

CYP2D6 is a phase I drug-metabolizing enzyme, not directly involved in body weight regulation. In the context of weight loss, it is occasionally mentioned in pharmacogenetics—for example, when medications like bupropion (combined with naltrexone) or certain antidepressants that affect appetite are used. However, the evidence for a meaningful role of CYP2D6 variants in weight loss is weak. Some GWAS have reported associations, but no clinical guidelines recommend CYP2D6 genotyping before starting a diet or exercise program. Key drivers of weight loss remain calorie balance, macronutrient composition, physical activity, and other genetic factors (e.g., FTO, MC4R). A DNA test for CYP2D6 may provide insights into how you metabolize certain drugs, but it does not replace blood tests or nutritional counseling. Its relevance for weight loss is low—best classified as mechanistic/unclear rather than evidence-based. Be cautious of marketing claims that overstate its importance.